Clinical Trials

Chapter Opening — A Patient's Story

James, a 68-year-old retired teacher, was diagnosed with metastatic castration-resistant prostate cancer. After two lines of standard treatment, his PSA continued to rise. His oncologist mentioned a clinical trial testing a new combination of a radioligand therapy with an immunotherapy drug. James was hesitant — he imagined being a "guinea pig" and worried about getting a sugar pill instead of real treatment. After learning more, he enrolled. The investigational combination shrank his tumors significantly, and his PSA dropped by over 90%. Two years later, that combination became an FDA-approved treatment option. James often says, "I didn't just help myself — I helped every man who comes after me."

Part 1: What Is a Clinical Trial?

A clinical trial is a carefully designed research study conducted in human volunteers to answer specific questions about new treatments, tests, or ways to prevent or detect disease.¹ Clinical trials are the only way that new cancer treatments move from the laboratory to your doctor's office. Every treatment available today for prostate cancer — every surgery technique, every radiation approach, every medication — was once tested in a clinical trial before it was approved.²

Clinical trials are not experiments done on unsuspecting patients. They are highly regulated, closely monitored studies with strict rules designed to protect participants.³ Every clinical trial must be approved by an ethics review board before a single patient can enroll, and every participant must give informed consent — meaning they fully understand what the study involves before agreeing to participate.⁴

Types of clinical trials include:

• Treatment trials — Test new drugs, drug combinations, radiation techniques, surgical approaches, or other therapies
• Prevention trials — Test whether certain medications, vitamins, or lifestyle changes can reduce the risk of developing cancer (for example, the Finasteride Prevention Trial discussed in Chapter 2)
• Screening and detection trials — Test new ways to find cancer earlier or more accurately (for example, new biomarkers or imaging techniques)
• Quality of life (supportive care) trials — Test ways to improve comfort and quality of life during and after treatment (for example, managing side effects of hormone therapy)
• Diagnostic trials — Test better ways to identify or classify a disease (for example, new genomic tests)

Part 2: The Phases of Clinical Trials

Before any new treatment reaches your pharmacy or hospital, it goes through a step-by-step testing process. Think of it like building a house — you must lay the foundation before you put up the walls, and you must put up the walls before you add the roof. Each phase builds on the knowledge gained from the previous one.⁵ ⁶

Before Human Testing: Preclinical Research

Before any treatment is tested in people, it is studied extensively in the laboratory — in cells grown in dishes (called "in vitro") and in animal models. This can take years. Only treatments that show promise and acceptable safety in the laboratory move forward to human testing.

Phase I — "Is It Safe?"

• Purpose: To find the safest dose and identify side effects
• Number of participants: Usually 15–30 patients (sometimes up to 80)
• What happens: Small groups of patients receive the treatment at increasing doses. Researchers carefully monitor for side effects. The goal is to find the highest dose that can be given safely — called the "maximum tolerated dose"
• Who participates: Often patients who have exhausted standard treatment options, though increasingly patients with earlier-stage disease are included
• Important to know: The primary goal is safety, not cure. However, some patients do respond to the treatment. Modern phase I trials in oncology, especially those testing targeted therapies, have shown response rates of 20% or higher in some cases⁷
• Duration: Months to a year

Phase II — "Does It Work?"

• Purpose: To determine whether the treatment has an effect on the cancer and to further evaluate safety
• Number of participants: Usually 25–100+ patients
• What happens: Patients with a specific type and stage of cancer receive the treatment. Researchers measure whether tumors shrink, PSA levels drop, or the cancer stops growing
• Important to know: Phase II trials may or may not have a comparison group. They help researchers decide whether the treatment is promising enough to move to the larger, more definitive Phase III trial
• Duration: One to three years

Phase III — "Is It Better Than What We Already Have?"

• Purpose: To compare the new treatment against the current standard treatment
• Number of participants: Usually hundreds to thousands of patients
• What happens: Patients are randomly assigned (randomized) to receive either the new treatment or the current standard treatment. This is the gold standard of medical evidence
• Important to know: This is the phase that most directly leads to FDA approval. If the new treatment proves superior (or equivalent with fewer side effects), it can become the new standard of care
• Duration: Several years
• Examples in prostate cancer: The STAMPEDE trial, ENZAMET trial, PEACE-1 trial, and many others that changed how we treat prostate cancer today were all Phase III trials

Phase IV — "What Happens in the Real World?"

• Purpose: To monitor the treatment after it has been approved and is being used widely
• Number of participants: Thousands to tens of thousands
• What happens: Researchers track long-term side effects, effectiveness in diverse populations, and interactions with other treatments
• Important to know: These studies help identify rare side effects that may not have appeared in smaller earlier trials

How Long Does the Entire Process Take?

From initial laboratory discovery to FDA approval, the process typically takes 10 to 15 years. Only about 5–10% of drugs that enter Phase I testing eventually receive FDA approval.⁸ This is why clinical trial participation is so valuable — without volunteers, this process cannot happen.

Part 3: How Clinical Trials Are Designed

Understanding a few key concepts will help you feel more comfortable if you are ever offered a clinical trial.

Randomization

In many trials (especially Phase III), patients are randomly assigned to one treatment group or another — similar to flipping a coin. This is not done to trick you. It is done to make sure the groups being compared are as similar as possible, so that any difference in outcomes can be attributed to the treatment itself, not to differences between the patients.⁹

Important: You will never be randomly assigned to receive nothing. In cancer trials, the comparison group (called the "control arm") receives the current best standard treatment. You will always receive at least the standard of care.

Blinding

In some trials, neither the patient nor the doctor knows which treatment the patient is receiving. This is called "double-blinding." It prevents expectations from influencing how side effects are reported or how responses are measured. If a serious side effect occurs, the treatment assignment can always be revealed immediately ("unblinded") so your doctors can take appropriate action.

Placebo

A placebo is an inactive substance (like a sugar pill). In cancer clinical trials, pure placebos are rarely used alone. When a placebo is used, it is almost always added on top of the standard treatment. For example, a trial might compare "standard treatment + new drug" versus "standard treatment + placebo." This means every patient receives at least the standard treatment.¹⁰

Endpoints

Every trial has specific goals it is trying to measure, called "endpoints":

• Overall survival (OS) — How long patients live
• Progression-free survival (PFS) — How long before the cancer grows or spreads
• PSA response — Whether PSA levels drop significantly
• Quality of life — How treatment affects daily living
• Metastasis-free survival (MFS) — How long before cancer spreads to distant sites

(These terms were explained in detail in the Statistics chapter earlier in this book.)

Data Safety Monitoring Board (DSMB)

Every major clinical trial has an independent group of experts — not involved in the study — who regularly review the data while the trial is ongoing.¹¹ If the new treatment is clearly better or clearly worse than the standard, the DSMB can stop the trial early. This protects patients from continuing on an inferior treatment or ensures that a superior treatment becomes available sooner.

Part 4: Your Protections as a Participant

Clinical trials today have multiple layers of protection built in to keep you safe. These protections exist because of lessons learned from historical abuses in medical research.

Institutional Review Board (IRB)

Before any clinical trial can begin, it must be reviewed and approved by an Institutional Review Board (IRB) — an independent committee of doctors, scientists, ethicists, and community members who are not involved in the study.¹² ¹³ The IRB reviews:

• Whether the study is scientifically sound
• Whether the risks to participants are minimized and reasonable
• Whether informed consent is adequate
• Whether participant selection is fair
• Whether privacy protections are in place

The IRB continues to monitor the trial throughout its duration and can stop it at any time if safety concerns arise.

Informed Consent

Before you enroll in any clinical trial, you will receive a detailed document called the "informed consent form." This document explains:¹⁴

• The purpose of the study
• What treatments or procedures are involved
• What the known risks and potential benefits are
• What alternatives to participation exist
• How your privacy will be protected
• That participation is completely voluntary
• That you can withdraw at any time without penalty

Signing the informed consent form does not mean you give up any rights. It does not mean you cannot leave the study. It simply means you have been informed and you agree to participate at this time. You can change your mind at any point.

The Declaration of Helsinki and the Belmont Report

Modern research ethics are built on international principles established after historical abuses:¹⁵

• The Nuremberg Code (1947) — Established that voluntary consent is absolutely essential
• The Declaration of Helsinki (1964, updated regularly) — International ethical guidelines for medical research involving humans
• The Belmont Report (1979) — Established three core principles: Respect for Persons (autonomy and informed consent), Beneficence (maximize benefits, minimize harm), and Justice (fair distribution of research benefits and burdens)

The Common Rule

In the United States, the "Common Rule" is the federal policy that governs research involving human subjects. It requires IRB review, informed consent, and additional protections for vulnerable populations.¹⁶ The 2017 amendment to the Common Rule further strengthened protections by mandating single central IRB review for multisite trials and reducing unnecessary regulatory burden.

Part 5: What to Expect as a Participant

Before You Enroll

1. Screening: You will undergo tests (blood work, imaging, possibly a biopsy) to determine whether you meet the study's eligibility criteria
2. Informed consent discussion: A research team member will explain the study in detail and answer all your questions
3. Review period: You can take the consent form home, discuss it with family, and take as much time as you need before deciding

During the Trial

• You will follow a specific schedule of visits, tests, and treatments outlined in the study protocol
• You may have more frequent doctor visits and monitoring than with standard care — many patients view this as a benefit¹⁷
• You will be asked to report any side effects or changes in how you feel
• The research team is available to answer questions throughout the study
• You may be asked to complete quality-of-life questionnaires

Your Rights During the Trial

• You can ask any question at any time
• You can withdraw from the study at any time for any reason, without it affecting your regular medical care
• You will continue to receive medical care whether or not you remain in the study
• Your personal information is kept confidential

After the Trial

• You will continue to be monitored for a period of time after the study treatment ends
• You will be informed of the study results when they become available
• If the experimental treatment proved beneficial, arrangements may be made for you to continue receiving it (called "compassionate use" or "expanded access")

Part 6: Finding Clinical Trials

There are several ways to find clinical trials that may be right for you:

Ask Your Doctor

This is the most important first step. Your oncologist, urologist, or radiation oncologist may know of trials at their institution or at nearby centers. Studies show that the most common reason patients do not participate in clinical trials is that no one spoke to them about the option.¹⁸ Do not be afraid to ask: "Are there any clinical trials that might be appropriate for me?"

ClinicalTrials.gov

This is the largest database of clinical trials in the world, maintained by the U.S. National Library of Medicine. Every clinical trial conducted in the United States (and many international trials) must be registered here. You can search by:

• Disease (e.g., "prostate cancer")
• Treatment type (e.g., "radiation therapy," "immunotherapy")
• Location (your city or state)
• Phase (Phase I, II, III)
• Status (recruiting, not yet recruiting, completed)

Website: www.clinicaltrials.gov

Cancer Center Trial Finders

Most major cancer centers have their own clinical trial search tools on their websites. NCI-designated comprehensive cancer centers often have the largest portfolios of available trials.

Advocacy Organizations

• Prostate Cancer Foundation (PCF): www.pcf.org — Maintains a clinical trial search tool
• ZERO — The End of Prostate Cancer: www.zerocancer.org
• Us TOO International: www.ustoo.org
• American Cancer Society: www.cancer.org
• National Cancer Institute (NCI): www.cancer.gov — Offers a trial search tool and a Cancer Information Service (1-800-4-CANCER) with specialists who can help match you to trials

Trial Matching Services

Several organizations offer free personalized trial matching:

• EmergingMed — Free trial matching for prostate cancer patients
• NCI Cancer Information Service — Call 1-800-4-CANCER
• Patient advocacy organizations — Many offer navigator services to help identify appropriate trials

Part 7: Costs and Insurance Coverage

One of the biggest concerns patients have about clinical trials is cost. Here is what you need to know:¹⁹ ²⁰

What Is Typically Covered by the Trial Sponsor

• The investigational drug or treatment itself
• Tests and procedures required solely for the research (not part of standard care)
• Additional monitoring required by the study protocol

What Is Typically Covered by Your Insurance

• Routine patient care costs — the same tests, doctor visits, and treatments you would receive even if you were not in the trial
• Management of side effects
• Standard-of-care treatments given as part of the trial

The Affordable Care Act (ACA) Protection

Since 2014, the ACA requires most private health insurance plans to cover routine patient care costs for individuals participating in approved clinical trials for cancer or other life-threatening diseases.²¹ This includes Phase I through Phase IV trials. The law prohibits insurers from denying coverage or discriminating against patients based on their participation in a clinical trial.

Medicare and Medicaid

• Medicare covers routine costs of qualifying clinical trials
• Medicaid coverage for clinical trial participation was expanded by the Clinical Treatment Act of 2020, which requires state Medicaid programs to cover routine costs²²

Out-of-Pocket Costs to Be Aware Of

Despite these protections, patients may still face costs related to:²³

• Travel to and from the trial site
• Lodging if the trial site is far from home
• Meals during treatment visits
• Lost wages from time off work
• Childcare during appointments
• Copays and deductibles for routine care

Studies have found that nearly half of patients in early-phase cancer trials spend at least $1,000 per month out of pocket.²⁴ It is important to ask the research team about potential costs before enrolling.

Financial Assistance

Many resources exist to help offset these costs:

• Some trial sponsors provide travel stipends or reimbursement
• The Patient Advocate Foundation (1-800-532-5274) offers case management services
• NCI and some advocacy organizations offer travel grants
• Some cancer centers have social workers who can help identify financial assistance programs

Part 8: Prostate Cancer Clinical Trials — What Is Being Studied Now

Prostate cancer is one of the most actively researched cancers in the world. Clinical trials are currently investigating:²⁵ ²⁶

New and Combination Drug Therapies

• Novel hormonal agents and combinations
• PARP inhibitors for patients with specific DNA repair mutations (BRCA1, BRCA2, ATM, and others)
• Immunotherapy combinations (checkpoint inhibitors with other agents)
• Antibody-drug conjugates targeting prostate cancer cells
• Bipspecific antibodies

Radiation Therapy Innovations

• Ultra-hypofractionated radiation (fewer, higher-dose treatments)
• FLASH radiotherapy (ultra-high dose rate radiation)
• Combination of radiation with novel systemic agents
• Radioligand therapies (such as Lutetium-177 PSMA) in earlier disease settings²⁷
• Proton therapy comparisons with photon-based radiation

Imaging and Biomarkers

• New PET tracers beyond PSMA
• Artificial intelligence for image interpretation
• Liquid biopsies (circulating tumor DNA) for monitoring treatment response
• New genomic and proteomic biomarkers

Surgical Innovations

• Focal therapy approaches
• Robotic surgery refinements
• Lymph node dissection extent studies

Supportive Care

• Exercise interventions during treatment
• Dietary interventions
• Management of treatment side effects
• Quality-of-life optimization

Part 9: Diversity in Clinical Trials — Why It Matters

Clinical trials have historically underrepresented certain populations, including Black men, Hispanic men, older adults, and patients from rural areas.²⁸ ²⁹ This is a significant problem because:

• Prostate cancer affects Black men at higher rates and often more aggressively than other racial groups
• If a treatment is tested primarily in one population, we cannot be certain it works equally well in others
• Genetic differences between populations may affect how drugs are metabolized or how cancers respond

Black men represent only about 6.7% of patients enrolled in therapeutic prostate cancer clinical trials, despite having the highest incidence and mortality rates.³⁰ Efforts are underway to address this disparity through community engagement, patient education programs, and removal of unnecessary eligibility restrictions.

If you are from an underrepresented group, your participation in clinical trials is especially valuable — not just for you, but for your entire community.

Part 10: Myth vs. Fact

Myth: "Clinical trials are a last resort — only for patients who have no other options."

Fact: Clinical trials are available at every stage of prostate cancer, from newly diagnosed low-risk disease to advanced metastatic cancer. In fact, experts recommend considering trials early in treatment, not just as a last resort.³¹

Myth: "I might get a sugar pill (placebo) instead of real treatment."

Fact: In cancer clinical trials, you will always receive at least the current standard of care. When placebos are used, they are added on top of standard treatment, not instead of it.

Myth: "Clinical trials are dangerous experiments."

Fact: Clinical trials are among the most closely monitored forms of medical care, with multiple layers of oversight including IRBs, data safety monitoring boards, and regulatory agencies.³²

Myth: "If I join a trial, I'm stuck — I can't leave."

Fact: Participation is completely voluntary. You can withdraw at any time, for any reason, without any penalty or effect on your regular medical care.

Myth: "My doctor will give me worse care if I refuse a trial."

Fact: Your doctor is ethically and legally obligated to provide you with the best possible care regardless of whether you participate in a trial.

Myth: "Clinical trials are free — there are no costs to me."

Fact: While the investigational treatment is usually free and insurance covers routine care costs, there may be out-of-pocket expenses for travel, lodging, and time off work. Ask about costs before enrolling.

Myth: "Only young, healthy patients can join clinical trials."

Fact: Many trials specifically seek older patients and those with other medical conditions, because these are the patients who will ultimately use the treatments in the real world.

Myth: "Clinical trials only benefit future patients, not me."

Fact: While advancing science is a major benefit, participants often receive access to cutting-edge treatments before they are widely available, along with closer monitoring and care from a dedicated research team.³³

Part 11: Questions to Ask Your Doctor About Clinical Trials

About the trial itself:

1. Are there any clinical trials that might be appropriate for my type and stage of prostate cancer?
2. What is the purpose of this trial? What phase is it?
3. What treatment will I receive? Is there a chance I will receive a placebo?
4. How does this trial compare to my current treatment options?
5. What are the potential benefits and risks?

About logistics:

1. How long will the trial last?
2. How often will I need to come in for visits?
3. Will I need to travel to a different center?
4. What tests and procedures are involved?
5. What costs will I be responsible for?

About my rights:

1. Can I leave the trial at any time?
2. What happens to my care if I leave the trial?
3. Who will be monitoring my safety during the trial?
4. Will I be told the results of the study?
5. If the treatment works for me, can I continue receiving it after the trial ends?

About eligibility:

1. What are the eligibility requirements?
2. Will my other medical conditions affect my eligibility?
3. Do I need to stop any current medications?
4. Is there a washout period before I can start?
5. Can I get a second opinion about whether this trial is right for me?

Part 12: Making the Decision — A Framework

Deciding whether to participate in a clinical trial is a personal decision. Here is a framework to help you think it through:

Consider the Potential Benefits

• Access to new treatments not yet available to the public
• Closer monitoring and more frequent check-ups
• Contributing to medical knowledge that may help others
• Potential for better outcomes than standard treatment

Consider the Potential Risks

• Unknown side effects from new treatments
• The treatment may not work for you
• More frequent visits and tests (time commitment)
• Possible out-of-pocket costs for travel and related expenses

Talk to People You Trust

• Your oncologist and other members of your medical team
• Your family and close friends
• Other patients who have participated in trials (support groups can help connect you)
• A patient navigator or social worker at your cancer center

Take Your Time

Most prostate cancer decisions — including the decision to join a clinical trial — do not need to be made immediately. Ask for time to review the informed consent document, do your research, and discuss with your loved ones. A good research team will never pressure you into a quick decision.

Key Takeaways

• Clinical trials are the engine of medical progress — every treatment available today was once tested in a clinical trial
• Multiple layers of protection exist to keep you safe, including IRBs, informed consent, data safety monitoring boards, and federal regulations
• You will always receive at least the standard of care — placebos in cancer trials are added on top of standard treatment, not instead of it
• Participation is voluntary — you can leave at any time without affecting your regular care
• Ask your doctor — the most common reason patients do not participate is that no one told them about the option

Support Resources

• ClinicalTrials.gov: www.clinicaltrials.gov — Search for trials by disease, location, and phase
• National Cancer Institute: www.cancer.gov/clinicaltrials — Trial search and Cancer Information Service (1-800-4-CANCER)
• Prostate Cancer Foundation: www.pcf.org/clinical-trials
• ZERO — The End of Prostate Cancer: www.zerocancer.org
• Patient Advocate Foundation: www.patientadvocate.org — Help with insurance and financial barriers (1-800-532-5274)
• EmergingMed: Free personalized trial matching
• Us TOO International: www.ustoo.org — Peer support and trial information

References

1. 1. Fisher B. Clinical trials for the evaluation of cancer therapy. Cancer. 1984;54(11 Suppl):2609-2617.
2. 2. Simon R. Randomized clinical trials in oncology: principles and obstacles. Cancer. 1994;74(9 Suppl):2614-2619.
3. 3. Lapid MI, Clarke BL, Wright RS. Institutional review boards: what clinician researchers need to know. Mayo Clin Proc. 2019;94(3):515-525.
4. 4. Tolchin B, Conwit R, Epstein LG, Russell JA. AAN position statement: ethical issues in clinical research in neurology. Neurology. 2020;94(15):661-669.
5. 5. Darrow JJ, Avorn J, Kesselheim AS. FDA approval and regulation of pharmaceuticals, 1983-2018. JAMA. 2020;323(2):164-176.
6. 6. Diez Pascual C. Clinical drug trials: the path to the patient. Methods Mol Biol. 2021;2296:411-421.
7. 7. Guerra M, Alouani E, Hueso T, et al. Relevance, risks, and benefits of early-phases clinical trials participations for patients with hematological malignancies from 2008 to 2023. Eur J Haematol. 2025;114(1):89-97.
8. 8. Spreafico A, Hansen AR, Abdul Razak AR, Bedard PL, Siu LL. The future of clinical trial design in oncology. Cancer Discov. 2021;11(4):822-837.
9. 9. Gehan EA. Clinical trials in cancer research. Environ Health Perspect. 1979;32:31-48.
10. 10. Kearns C, Feighery R, Mc Caffrey J, et al. Understanding and attitudes toward cancer clinical trials among patients with a cancer diagnosis. Cancers. 2020;12(7):E1921.
11. 11. Fernandez Lynch H, Tillman I, Summers EI, Mah E. Preserving research ethics oversight amid decimation of the research enterprise. JAMA. 2025;333(24):2143-2144.
12. 12. Lapid MI, Clarke BL, Wright RS. Institutional review boards: what clinician researchers need to know. Mayo Clin Proc. 2019;94(3):515-525.
13. 13. Fernandez Lynch H, Tillman I, Summers EI, Mah E. Preserving research ethics oversight amid decimation of the research enterprise. JAMA. 2025;333(24):2143-2144.
14. 14. Tolchin B, Conwit R, Epstein LG, Russell JA. AAN position statement: ethical issues in clinical research in neurology. Neurology. 2020;94(15):661-669.
15. 15. Tolchin B, Conwit R, Epstein LG, Russell JA. AAN position statement: ethical issues in clinical research in neurology. Neurology. 2020;94(15):661-669.
16. 16. Tolchin B, Conwit R, Epstein LG, Russell JA. AAN position statement: ethical issues in clinical research in neurology. Neurology. 2020;94(15):661-669.
17. 17. Roberts NA, Davis ID, Wyld D, et al. How to support participants in urogenital and prostate clinical trials: a qualitative perspective. Psycho-Oncology. 2025;34(7):e70214.
18. 18. Prostate Cancer Health Education Network (PHEN) clinical trial learning sessions. J Clin Oncol. 2025;43(suppl 10; abstr 145).
19. 19. Williams CP, Deng L, Caston NE, et al. Understanding the financial cost of cancer clinical trial participation. Cancer Med. 2024;13(8):e7185.
20. 20. Winkfield KM, Phillips JK, Joffe S, et al. Addressing financial barriers to patient participation in clinical trials: ASCO policy statement. J Clin Oncol. 2018;36(33):3331-3339.
21. 21. Kircher SM, Benson AB, Farber M, Nimeiri HS. Effect of the Accountable Care Act of 2010 on clinical trial insurance coverage. J Clin Oncol. 2012;30(5):548-553.
22. 22. Williams CP, Deng L, Caston NE, et al. Understanding the financial cost of cancer clinical trial participation. Cancer Med. 2024;13(8):e7185.
23. 23. Donzo MW, Nguyen G, Nemeth JK, et al. Effects of socioeconomic status on enrollment in clinical trials for cancer: a systematic review. Cancer Med. 2024;13(1):e6905.
24. 24. Williams CP, Deng L, Caston NE, et al. Understanding the financial cost of cancer clinical trial participation. Cancer Med. 2024;13(8):e7185.
25. 25. MacDonald LP, Fang AM, Tang C, Chapin BF. Current and upcoming trials in localized prostate cancer. Urol Clin North Am. 2026;53(1):171-181.
26. 26. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 1.2026.
27. 27. Sandhu S, Joshua AM, Emmett L, et al. [¹⁷⁷Lu]Lu-PSMA-617 in combination with pembrolizumab for treatment of metastatic castration resistant prostate cancer (PRINCE). Lancet Oncol. 2026;27(4):470-479.
28. 28. Eggly S, Senft N, Kim S, et al. Addressing multilevel barriers to clinical trial participation among Black and White men with prostate cancer through the PACCT study. Cancer Med. 2023;12(7):8604-8613.
29. 29. Eldridge L, Goodman NR, Chtourou A, et al. Barriers and opportunities for cancer clinical trials in low- and middle-income countries. JAMA Netw Open. 2025;8(4):e257733.
30. 30. Prostate Cancer Health Education Network (PHEN) clinical trial learning sessions. J Clin Oncol. 2025;43(suppl 10; abstr 145).
31. 31. Peppercorn JM, Smith TJ, Helft PR, et al. American Society of Clinical Oncology statement: toward individualized care for patients with advanced cancer. J Clin Oncol. 2011;29(6):755-760.
32. 32. Asher N, Raphael A, Wolf I, Pelles S, Geva R. Oncologic patients' misconceptions may impede enrollment into clinical trials. BMC Med Res Methodol. 2022;22(1):5.
33. 33. Kubilay Tolunay P, Erol C, Kahraman S, et al. Understanding of clinical trials among patients with cancer and their relatives. JAMA Netw Open. 2025;8(1):e2457020.